Key ECCs, some of which Intrexon outlines specific equity stakes in and/or license fees or royalty payments due, are listed as follows:
•ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), to develop and commercialize therapeutics in the field of cancer treatment in humans;
•Elanco, the animal health division of Eli Lilly and Company (NYSE: LLY); targeting certain chronic diseases associated with aging in companion animals as well as the prevention of certain infectious diseases in pigs;
•Fibrocell Science, Inc. (OTCBB: FCSC), in the research phase for the treatment of recessive dystrophic epidermolysis bullosa, a rare and genetically based blistering disorder.
•Oragenics, Inc. (OTCBB: OGEN), in the research phase to develop and commercialize lantibiotics;
•Synthetic Biologics, Inc. (NYSE: SYN), or Synthetic Biologics. The lead therapeutic program of this ECC is currently in preclinical development;
•AquaBounty Technologies, Inc. (AIM: ABTX), for a new strain of fish called the AquAdvantage Salmon reaching marketable size in around half the time of conventional salmon;
•AmpliPhi BioSciences Corp. (OTCBB: APHB), to develop and commercialize new bacteriophage-based therapies to target specific antibiotic resistant infections;
•Soligenix, Inc. (OTCQB: SNGX), to develop and commercialize human monoclonal antibody therapies for the treatment of melioidosis;
•and BioLife Cell Bank, Inc., or BioLife, in an option to produce new treatments for spinal muscular atrophy.
In some aspects Intrexon is a holding company. In other aspects it is a technology licensing company. Either way, the company will be one to watch. With the stakes owned it is possible that some of these could have huge payoffs for it in the future.
im curious how ziopharm will fair in the il12 viral vector platform since they are competing with oncosec il12 via electroporation
oncosec has a fully enrolled 24 patient all highest dose while ziop's 30 patient trial seems to be about half enrolled and only half is in the high dose groups so 12 patients
so my feeling is that oncosec could be more likely to get fast track and accelerated approval first if that is even possible but hard to say if not then ziopharm will just trail behind them for a good while
again the proprietary is less for ziop since they do not need a bulky electroporation machine just vaccine solute w/ vector and oral ligand activator
Is Ziopharm's trial for IL-12 fully enrolled yet? OncoSec's Phase II results with electroporation are to be released within a month, but there's no word on how well Ziopharm's trial is progressing. They originally said results to be released in 1H2013.
Positive results from either trial should propel both stocks much higher. I believe the results will be both safe and positive.